FDA releases FAQs on remdesivir EUA, antibody tests

The Food and Drug Administration yesterday updated its FAQs on the emergency use authorization of remdesivir for use on certain hospitalized COVID-19 patients.

The document includes information on the changes to Gilead’s fact sheets for health care providers and patient caregivers.

FDA this week also posted a patient-and-consumer-focused FAQ about SARS-CoV-2 antibody, or serology, testing, including a guide to understanding test results and where to obtain them.